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Background: The EGFR 3′ untranslated region (UTR) harbors a polyadenine repeat which is polymorphic (A13/A14)
and undergoes somatic deletions in microsatellite instability (MSI) colorectal cancer (CRC). These mutations could
be oncogenic in colorectal tissue since they were shown to result into increased EGFR mRNA stability in CRC cell
lines.
Methods: First, we determined in a case control study including 429 CRC patients corresponding to different
groups selected or not on age of tumor onset and/or familial history and/or MSI, whether or not, the germline
EGFR A13/A14 polymorphism constitutes a genetic risk factor for CRC; second, we investigated the frequency of
somatic mutations of this repeat in 179 CRC and their impact on EGFR expression.
Results: No statistically significant difference in allelic frequencies of the EGFR polyA repeat polymorphism was
observed between CRC patients and controls. Somatic mutations affecting the EGFR 3′UTR polyA tract were
detected in 47/80 (58.8%) MSI CRC versus 0/99 microsatellite stable (MSS) tumors. Comparative analysis in 21 CRC
samples of EGFR expression, between tumor and non malignant tissues, using two independent methods showed
that somatic mutations of the EGFR polyA repeat did not result into an EGFR mRNA increase.
Conclusion: Germline and somatic genetic variations occurring within the EGFR 3′ UTR polyA tract have no impact
on CRC genetic risk and EGFR expression, respectively. Genotyping of the EGFR polyA tract has no clinical utility to
identify patients with a high risk for CRC or patients who could benefit from anti-EGFR antibodies.
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Colorectal cancer (CRC) is the third most commonly
diagnosed cancer in males and the second in females
with 1.2 million new cases and 608,700 deaths estimated
to have occurred worldwide in 2008 [1]. In its early
stage, CRC represents a curable disease. However, 20–
50% of patients with newly diagnosed CRC will develop* Correspondence: richard.sesboue@univ-rouen.fr
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distribution, and reproduction in any mediumsecondary metastases (mCRC) [2]. A major advance in
the treatment of mCRC has been achieved thanks to the
development of targeted therapies. Accordingly, two
antibodies, cetuximab and panatimumab, which select-
ively target the extracellular domain of the epidermal
growth factor receptor (EGFR), have been approved for
the treatment of metastatic diseases. The combination of
these targeted molecules with conventional chemother-
apy (5-FU, Irinotecan, Oxaliplatin) has led to significant
improvement in response rate, progression free survival
and overall survival in first line, as well as second or
third line treatment of mCRC [3-8]. This efficiencyCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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oncogenic in CRC. However clinical trials have shown a
high individual variability of response and outcome in
mCRC patients, which has highlighted the need for iden-
tification of reliable markers predictive of response to
treatment. The only molecular marker predictive of the
response of the anti-EGFR mAbs, which has been unam-
biguously validated in mCRC by numerous studies, is
the presence of KRAS activating mutations as a marker
of resistance to anti-EGFR [9,10]. However the occur-
rence of KRAS mutations only accounts for 35–45% of
non-responsive patients [11]. Remarkably, the mecha-
nisms of EGFR activation in CRC have not been charac-
terized in most of the patients. This contrasts with the
situation observed in lung adenocarcinoma where the
key mechanism of EGFR activation, underlying sensitiv-
ity to EGFR inhibitors, corresponds to activating muta-
tions within the EGFR tyrosine kinase domain [12,13].
Indeed, in CRC, the amplification of EGFR resulting in
overexpression and associated to sensitivity to anti-EGFR is
detected in only 10–15% of CRC [14-17]. Overexpression
of the EGFR ligands, amphiregulin and epiregulin, has been
reported to be associated to sensitivity to anti-EGFR mAbs
[18,19].
The EGFR gene contains within the 3′ untranslated
region (UTR), 281 bp downstream from the stop codon,
a polyadenine tract which is polymorphic (A13/A14).
Mono or dinucleotide deletions within this polyA tract
have been detected in colon cancer cell lines or CRC
exhibiting microsatellite instability (MSI) [20]. These dele-
tions have been shown to stabilize EGFR mRNA, to result
in EGFR overexpression in vitro and to increase sensitivity
to anti-EGFR antibodies in xenografts [20]. This prompted
us to investigate, in CRC patients, the oncogenic impact
of genetic variations affecting this regulatory region. To
this aim, we used two complementary approaches: first,
we determined, in a case control study, whether or not the
germline EGFR A13/A14 polymorphism constitutes a
genetic risk factor for CRC; second we investigated the




The germline EGFR A13/A14 polymorphism was inves-
tigated in a total of 429 CRC patients of French origin,
corresponding to 4 groups: (1) Patients with CRC not
selected on age of tumor onset or familial history (n =
179). This group, enriched in MSI tumors, corresponded
to 80 MSI and 99 MSS CRC, as determined with a
mononucleotide pentaplex panel [21]; (2) patients se-
lected according to three different criteria suggestive of
an increased genetic risk for CRC, but without detect-
able mutations in genes involved in Lynch syndrome oradenomatous polyposis (n = 62): (i) CRC before 61 years
of age (or high-risk adenoma before 51 years of age)
with a first-degree relative presenting with CRC; (ii)
CRC before 51 years of age (or high-risk adenoma before
41 years of age); or (iii) multiple primitive colorectal tu-
mors in the same patient, the first one diagnosed before
61 years of age if cancer or before 51 years of age if high-
risk adenoma; (3) patients with Lynch syndrome harbor-
ing a mutation in one of the mismatch repair (MMR)
genes (n = 100); (4) non selected sporadic CRC (n = 88).
For the first group, germline EGFR A13/A14 polymorph-
ism was genotyped from DNA extracted from paraffin
embedded (FFPE) or frozen non malignant colorectal tis-
sues. For the three others, DNA was extracted from per-
ipheral blood samples after informed consent for genetic
analyses had been obtained. DNA extraction from blood
samples was performed using the FlexiGene kit (Qiagen),
from FFPE samples, after manual macrodissection, using
the Ambion RecoverAll kit (Applied Biosystems) and,
from frozen samples, using the NucleospinW Tissue kit
(Macherey-Nagel EURL). EGFR allelic frequency in the
general population was determined from 170 French con-
trols, aged from 46 to 92 years.
Somatic mutations of the EGFR repeat were screened
from FFPE or frozen tumor samples from the 179 CRC
samples (group 1). For each patient, genomic DNA was
extracted from paired tumor and normal colorectal tissues.
For each subject, a written consent had been obtained
to perform genetic analyses either on blood or colorectal
tissue and, in compliance with the Helsinki Declaration,
the research programs on the molecular genetics of
colorectal cancer had been approved by the ethics com-
mittee of Rouen and Nantes University hospitals.
Genotyping of the EGFR 3’UTR polyA repeat
The EGFR 3’UTR polyA tract was amplified from 100 ng
genomic DNA by fluorescent multiplex PCR targeting
EGFR and PCBD2, as control (primers in Additional file
1). Amplification was performed in a final volume of 25
μl containing 1U of Diamond TaqDNA PolymeraseW
(Eurogentec) and 100 ng DNA, with the following con-
ditions: after an initial step of denaturation at 95°C for 3
minutes, 24 PCR cycles consisting of denaturation at 94°C
for 25 seconds, annealing at 58°C for 25 seconds, and
extension at 72°C for 25 seconds, followed by a final ex-
tension step at 72°C for 25 seconds. Amplicons were sepa-
rated on an ABI Prism 3100 DNA sequencer (Applied
Biosystems), and the resulting fluorescence profiles
were analysed using the Genescan software (version 3.7,
Applied Biosystems). To ensure an accurate genotyping,
we constructed molecular calibrators. To this end, the
3’UTR polyA tract was amplified from genomic DNA
extracted from several cell lines obtained from the
American Type Culture Collection (LGC Standards):
Figure 1 Analysis of the germline EGFR 3′UTR polyA repeat
polymorphism, using fluorescent multiplex PCR. A: Representative
patterns obtained with cloned and sequenced amplicons
corresponding to A13, A13/A14 and A14 repeats, from top to
bottom. B: Representative patterns obtained with genomic DNA
extracted from non malignant colorectal tissues corresponding to
A13, A13/A14 and A14 repeats, from top to bottom; the peak to the
right corresponds to the control (PCBD2) gene.
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(CCL-221) and SW48 (CCL-231). The amplicons were
then cloned into the BamH1-Xho1 site of pCDNA 3.1
(Clontech) and sequenced. Homozygous genotypes ran-
ging from 10 to 14A were identified and heterozygous
samples were obtained by mixing equal quantities of
homozygous amplicons. Determination of the EGFR
genotype was performed by superimposition of the pro-
files to that obtained from these molecular calibrators.
Screening for EGFR somatic mutations was performed for
each patient by superimposition of the profiles generated
from tumor and paired non malignant CRC tissue.
Measurement of EGFR expression
Frozen tumor tissue (TT) and paired normal tissue (NT)
were collected from 21 CRC patients; normal tissue was
obtained remote from the tumor, near the section boundary;
for tumor tissue, an adjacent control fragment was em-
bedded in paraffin, cut and stained with hemalun-eosin-
safran to estimate the percentage of cancerous cells (on
average 55%). Total RNA was extracted using the total
RNA isolation Nucleospin RNA IIW kit (Macherey-Nagel)
following the manufacturer’s protocol. RNA quality was
assessed by ExperionW (BioRad) analysis. Total RNA
(1.5 μg) was reverse transcribed using the SuperScript II re-
verse transcriptase for cDNA synthesis (Life Technologies)
in a final volume of 40 μl at 40°C during 50 minutes in the
presence of RNAse inhibitors (RNaseOUT™, Invitrogen).
Two methods were used to accurately measure EGFR ex-
pression: quantitative RT-PCR was performed with the
syber green gene expression assay for EGFR and, as internal
control, PGK (primers in Additional file 1); reaction was
performed with 100 ng of cDNA in the 7300 real time PCR
systemW apparatus (Applied Biosystem). The level of EGFR
mRNA was calculated by relative quantitation using the
comparative ΔΔCT threshold cycle method [22]. A semi
quantitative RT-PCR (RT-QMPSF) assay was also devel-
oped, as previously described [23], and performed in a final
volume of 50 μl using 2.5 μl of cDNA and 0.5 μl of Pwo
DNA PolymeraseW (Roche), using two endogenous control
genes, SF3A and PGK (primers in Additional file 1). The
PCR conditions were as follows: 95°C for 15 seconds
followed by 27 cycles at 94°C for 15 seconds and 58°C for
30 seconds and 72°C for 45 seconds. Amplicons were
separated on an ABI Prism 3100 DNA sequencer and the
resulting fluorescence profiles were analysed using the
Genescan software. The areas under curve (AUC) of
amplicons were compared and normalized with the average
AUC of control amplicons (SF3A and PGK).
In silico analysis of mRNA secondary structures
Four web servers were used to modelize the EGFR
mRNA secondary structure according to the number of
adenines in the 3′ UTR polyA tract [24-27].Results
We genotyped the EGFR polyA repeat in non malignant
colorectal tissue or blood from 429 patients with CRC
corresponding to different groups of CRC patients se-
lected or not on age of tumor onset and/or familial
history and/or MSI. To ensure an acurate genotyping
(Figure 1), we used, as calibrators, cloned EGFR polyA
repeats the size of which had been determined by se-
quencing. Allelic frequencies observed in CRC patients
and controls are given in Table 1. Allelic frequencies
were in Hardy-Weinberg equilibrium in patients and
controls. The frequency of the major allele (A13) was es-
timated in controls and patients to 76.5 and 72.8%,
Table 1 Allelic frequency of the EGFR 3′UTR polyA repeat in CRC patients and controlsa
Controls Patients
Group 1 Group 2 Group 3 Group 4 Total
MSS MSI Total
Number 170 99 80 179 62 100 88 429
Age range (median) 46–92 (72) 66–88 (67) 25–99 (71) 25–99 (71) 46–62 (52) 19–66 (42) 70–92 (75) 25–99 (62)
A12 0.6% (0–2) - - - - 1% (0–4) - 0.2%(0–1)
A13 76.5% (71–81) 70.7% (64–77) 73.7% (66–80) 72.1% (67–77) 74.2% (65–81) 73% (66–79) 73.3% (66–79) 72.8% (70–76)
A14 22.9% (18–28) 29.3% (23–36) 26.3% (20–34) 27.9% (23–33) 25.8% (18–34) 26% (20–33) 26.7% (20–34) 26.9% (24–30)
p valueb 0.15 0.46 0.12 0.90 0.97 0.30 0.19
a For each allelic frequency, confidence interval is given in brackets.
b The p value in each patient group corresponds to the comparison with controls (chi-2 test).
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lelic frequencies of the EGFR polyA repeat was observed
between patients and controls and between each group
of patients and controls (Table 1).
We then screened 179 patients with CRC for somatic
mutations of the EGFR polyA repeats, by comparing, for
each patient, the PCR profile obtained from tumor to
that from paired non malignant tissue (Figure 2). As
shown in Figure 2B, somatic EGFR polyA mutations
could easily be detected by a clear shift of the EGFR
fluorescent peak observed in tumors. In the 99 MSS
CRC, we observed no somatic EGFR polyA mutation. In
contrast, we detected an EGFR polyA mutation in 47/80
(58.8%) MSI CRC. The detected mutations always
corresponded to adenine deletion and no gain was ob-
served. The number of deletions ranged from 1 to 4 ade-
nines and the total number of deletions observed on
both alleles was: 1 (25.5%), 2 (27.7%), 3 (17%), 4 (12.8%),
5 (10.6%), 6 (2.1%), 7 (2.1%) and 8 (2.1%). There was no
significant difference (chi-2 test, p = 0.70) in somatic
mutation frequency (Table 2) in patients with A13/A13,
A13/A14 and A14/A14 genotypes.
To address the specificity of somatic mutations affect-
ing the EGFR 3′UTR polyA tract in MSI CRC, we evalu-
ated in 10 MSI with EGFR mutations and 10 MSS CRC
samples the frequency of mutations within two other 3′
UTR polyA tracts sharing structure similar to that of the
EGFR: a polyA(15) in RAB31 (member RAS oncogene
family) and a polyA(14) in ATP6V1G1 (ATPase V1 sub-
unit G1). In all MSI CRC samples with EGFR polyA
tract mutations, we also found mutations of RAB31 and
ATP6V1G1 polyA tracts, but no mutation was observed
in MSS tumors.
We analyzed the potential impact of the EGFR 3′UTR
polyA tract mutations on mRNA secondary structure
through bioinformatics prediction. Successive deletions
of adenine was not predicted to result in any significant
alteration of the mRNA structure and, in particular,
there was no modification of predicted binding sites formiRNAs (hsa-mir-146a/b, hsa-mir-133b, hsa-mir-7-1/2)
or regulating proteins (HuR: AU-rich elements).
We then determined the impact on EGFR expression
of the somatic EGFR polyA tract mutations detected in
MSI CRC, using real-time PCR quantitation of mRNA
and RT-QMPSF (Figure 3). These two methods applied
to 11 CRC with EGFR polyA mutation and 10 CRC with-
out mutation yielded identical results (r = 0.75, see
Additional file 2: Figure S1A). In 10/11 mutated and 10/10
non mutated samples, we observed, as illustrated in
Figure 3, that the level of EGFR mRNA was lower in malig-
nant tissue, as compared to paired normal tissue, although
the difference was not significant. In the remaining mu-
tated sample, we observed a slight increase (×1.1) of EGFR
expression in tumor by comparison to normal tissue.
There was no influence of the total number of adenine de-
letions on EGFR mRNA levels, even in a sample exhibiting
up to 7 adenine deletions (see Additional file 2: Figure
S1B). In 8 tumor samples harboring two EGFR alleles of
different size and in 10 non malignant tissues from patients
with a heterozygous genotype, we could compare the
EGFR allelic expression by calculating the mRNA ratios
corresponding to the short / long allele. In both cases, we
did not observe an obvious allelic expression imbalance,
but only a slight increase of expression of the short allele,
as compared to the long one (mean 1.11 and 1.15,
respectively).
Finally, we evaluated whether the germline EGFR
polyA repeat polymorphism or mutational status in
tumor influence the risk of tumor recurrence in 64 pa-
tients with a localized form of CRC (stage I, II and III)
followed for at least two years. There was no difference
in the percentages of recurrence according to the germline
polyA polymorphism (p = 0.72), nor according to the ex-
istence or not of a somatic mutation (p = 0.72). In 18 pa-
tients with metastatic disease (stage IV) treated by anti-
EGFR (cetuximab or panitumumab), the disease control
rate was not influenced by the polyA tract polymorphism
(p = 0.78).
Figure 2 Detection of EGFR 3′UTR polyA tract somatic mutations, using fluorescent multiplex PCR. The profile generated from malignant
tissue (red) was superimposed on that obtained from distant non-malignant tissue (blue) after alignment of the control amplicons (peaks to the
right corresponding to PCBD2). A: Pattern observed in a non mutated sample with A13/A14 genotype. B: Pattern observed in a mutated sample
with A13/A14 genotype; notice in the tumor sample a shift of the peaks to the left corresponding to A11 and A12 repeats.
Table 2 Frequency of somatic deletions observed in the
EGFR 3′UTR polyA tract according to the germline







A13/A13 45 60.0 ± 2.1%
A13/A14 28 53.6 ± 3.5%
A14/A14 7 71.4 ± 12.6%
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We evaluated the biological impact, in patients with
CRC, of germline or somatic genetic variations occur-
ring within the EGFR 3′UTR polyA tract. First, we ob-
served that the EGFR polyA allelic frequency in 429
CRC patients was similar to that observed in a control
sample. Considering the genetic heterogeneity of CRC,
we constructed the patient sample with 4 different groups
selected or not on the basis of age of tumor onset or fa-
milial history or MSI status. The first group, composed of
179 CRC patients unselected on age of tumor onset or fa-
milial history, has been, on purpose, enriched in patients
with MSI tumors, which had been shown in the original
study of Yuan et al. [20] to exhibit a high rate of somaticEGFR mutations. The second group, constituted of 62 pa-
tients without detectable mutations within MMR or aden-
omatous polyposis genes but whose personal or familial
history was suggestive of an increased genetic risk, was
analyzed to determine whether or not the EGFR polyA
Figure 3 Analysis of EGFR expression in non malignant and tumor colorectal tissues using fluorescent multiplex RT-QMPSF. After
adjustment on peaks corresponding to control genes (PGK and SF3A, peaks on the right), amplicons from normal (in blue) and tumor (in red)
tissues are superimposed. A: Expression profiles in a non mutated sample from a patient with A13/A14 genotype. B: Expression profiles in a
mutated sample from a patient with A13/A14 genotype; notice in the tumor sample a shift of the peaks to the left corresponding to A9 and
A11 repeats.
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We also analyzed a series of 100 patients with Lynch syn-
drome to evaluate if the EGFR polyA polymorphism could
act as a modifier risk factor in patients harboring a MMR
gene mutation. Finally, the last group corresponded to 88
unselected sporadic CRC. In none of these groups, could a
significant difference in EGFR allelic frequencies with con-
trols be detected, suggesting that the EGFR 3′UTR polyA
polymorphism does not modify the genetic risk for CRC.
It could be argued that the size of the patient sample or
that of the different groups was insufficient to detect a sig-
nificant difference, but the allelic frequency between pa-
tients and controls were remarkably similar (Table 1). We
also screened for somatic mutations of the EGFR polyA
tract in the group of 179 CRC patients, whose genotypes
had been characterized and found that somatic mutations,
corresponding to deletions, were detected in 59% of the
80 MSI tumors but in none of the 99 MSS tumors. This
confirms, on a larger sample, the results observed by
Baranovskaya et al. [28], Yuan et al. [20] and Deqin et al.
[29] who had reported, from a series of 40, 16 and 36 MSI
CRC a mutation detection rate of 92.5%, 69% and 81%,
respectively. Nevertheless, we obtained two results which
argue against an oncogenic effect of these somaticmutations: first, the adenine deletions occurring in the 3′
UTR polyA tract did not show any specificity with respect
to EGFR since they could also be observed in 2 others
genes not involved in CRC: RAB31 and ATP6V1G1; there-
fore the high frequency of somatic EGFR polyA mutations
reported in MSI tumors by other studies and this work
probably reflects a particular sensitivity of mononucleo-
tide tracts to defective DNA mismatch repair system, as
recently reported for the polyT(20) tract of the MT1X
gene [30]; second, we found that these mutations did not
result into a significant increase of EGFR expression. In a
study focused on the CA repeat located within the EGFR
first intron, Baranovskaya et al. [28] have also observed, in
agreement with our results, that EGFR expression was de-
creased in MSI CRC. In a sample composed of 16 MSI
endometrial adenocarcinomas, Deqin et al. [29] have
reported that tumors with EGFR polyA deletions exhibit a
slight (1.6) but nevertheless not significant increase of
EGFR expression, as compared to that without mutations.
Our observation contrasts with results obtained by Yuan
et al. [20]. Indeed, these authors had reported, in colon
MSI cancer cell lines, that a deletion within the EGFR
polyA tract increases in vitro the EGFR mRNA stability.
In CRC patients, we observed that, in the majority of the
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total level of EGFR mRNA was not increased but, in con-
trast, decreased and this result was obtained using two in-
dependent methods. The discrepancy observed between
both studies highlights the need to confirm in clinical
samples results previously obtained with cell lines which
may not be representative of the complexity of gene regu-
lation in clinical samples, because of the genetic drift oc-
curring during in vitro culture.
Conclusion
This study has raised several arguments showing that
genetic variations affecting the EGFR polyA repeat are
not involved in CRC development: (i) The EGFR polyA
polymorphism does not constitute a genetic risk factor
for CRC; (ii) somatic mutations of this repeat are com-
monly observed in MSI CRC, but their frequency re-
flects a sensitivity of this type of repeat to MSI and not a
specific selective advantage; (iii) somatic EGFR polyA
mutations do not result into an EGFR mRNA increase
in colorectal tissue. Therefore, genotyping of the EGFR
polyA tract has no clinical utility to identify patients
with a high risk for CRC or patients who could benefit
from anti-EGFR antibodies.
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Additional file 1: Table S1. Primer sequences.
Additional file 2: Figure S1. A: Correlation between RT-QMPSF
(abscissa) and qRT-PCR (ordinate) results obtained on 21 CRC samples;
mutated (♦) and non mutated (◊) samples. B: Ratio TT/NT obtained by
qRT-PCR with respect to the total number of mutations (samples to the
left correspond to non mutated tumor tissues); mutated (♦) and non
mutated (◊) samples.
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